Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093863 | 1.00 | SCN5A (0.42) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 | |
| SCHEMBL4102819 | 0.84 | SLC6A9 (0.45) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 | |
| SCHEMBL4088101 | 0.84 | SLC6A9 (0.45) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 | |
| SCHEMBL13724557 | 0.83 | ALDH1A1 (0.48) | SCN5ASCN9AMEN1ALDH1A1POLB | |
| SCHEMBL13724564 | 0.83 | ALDH1A1 (0.48) | SCN5ASCN9AMEN1ALDH1A1POLB | |
| SCHEMBL4093033 | 0.82 | SCN5A (0.40) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 | |
| SCHEMBL4095513 | 0.82 | SCN5A (0.40) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 | |
| SCHEMBL4093117 | 0.80 | SLC6A9 (0.48) | SLC6A9MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL4092989 | 0.80 | SLC6A9 (0.48) | SLC6A9MEN1ALDH1A1POLBKMT2A | |
| SCHEMBL4093105 | 0.80 | SLC6A9 (0.42) | SCN5ASCN9ASLC6A9MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | SCN5A 329/4885SCN9A 3265/4885SLC6A9 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.